Want to see HK:2575 full AI Analyst Report?
Xuanzhu Biopharmaceutical Co., Ltd. Class H (2575) AI Stock Analysis
Xuanzhu Biopharmaceutical Co., Ltd. Class H
(HKEX:2575)
The overall score is heavily pressured by extremely weak technicals and negative valuation metrics, which reflect the market's skepticism. The company's financial position is a double-edged sword: a fortress balance sheet provides a critical safety net, but this is offset by massive, unmitigated cash burn and deep losses that show no immediate sign of abating. The stock is in a strong downtrend with no positive catalysts from earnings or corporate events to reverse sentiment.
Xuanzhu Biopharmaceutical Co., Ltd. Class H (2575) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 4.45B
- Dividend Yield
- ―
- Average Volume (3M)
- 1.98M
- Price to Earnings (P/E)
- -18.0
- Beta (1Y)
- 2.12
- Revenue Growth
- 237.19%
- EPS Growth
- 61.28%
- Country
- Hong Kong
- Employees
- 344
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Xuanzhu Biopharmaceutical Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Xuanzhu Biopharmaceutical Co., Ltd. is a Chinese enterprise dedicated to the research, production, and commercialization of both small-molecule chemical compounds and large-molecule biopharmaceuticals. The company's primary drug candidates include Co...
Xuanzhu Biopharmaceutical Co., Ltd. Class H Financial Statement Overview
Summary
Financial performance is highly polarized. Explosive revenue growth and a swing to positive gross margins signal commercial traction, but massive net losses and severe cash burn persist. The pristine, debt-free balance sheet provides a long runway, yet the rapid equity erosion and lack of a path to breakeven are major concerns.
Income Statement
35NegativeBalance Sheet
75PositiveCash Flow
30Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 116.94M | 56.15M | 32.63M | 32.04K | 0 | 0 |
| Gross Profit | 40.23M | 21.80M | -12.60M | -35.52M | -30.16M | 0 |
| EBITDA | -185.72M | -220.55M | -566.36M | -295.28M | -563.77M | -489.29M |
| Net Income | -234.79M | -266.26M | -603.29M | -332.12M | -595.70M | -566.28M |
Balance Sheet | ||||||
| Total Assets | 1.79B | 1.83B | 1.27B | 1.45B | 1.63B | 2.30B |
| Cash, Cash Equivalents and Short-Term Investments | 587.30M | 765.43M | 294.13M | 495.15M | 792.98M | 1.51B |
| Total Debt | 251.80K | 720.64K | 1.57M | 18.79M | 32.82M | 36.02M |
| Total Liabilities | 292.77M | 300.83M | 255.31M | 232.05M | 130.75M | 111.91M |
| Stockholders Equity | 1.50B | 1.53B | 1.02B | 1.22B | 1.50B | 2.18B |
Cash Flow | ||||||
| Free Cash Flow | -214.45M | -223.60M | -105.22M | -130.05M | -501.15M | -597.99M |
| Operating Cash Flow | -213.58M | -222.97M | -104.67M | -128.13M | -449.15M | -504.75M |
| Investing Cash Flow | 103.00M | 121.20M | 143.04M | 49.43M | -579.14M | 59.83M |
| Financing Cash Flow | 683.66M | 675.14M | -13.47M | -10.94M | -14.14M | 1.05B |
Xuanzhu Biopharmaceutical Co., Ltd. Class H Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2575, the sentiment is Negative. The current price of 7.73 is below the 20-day moving average (MA) of 8.39, below the 50-day MA of 9.01, and below the 200-day MA of 26.76, indicating a bearish trend. The MACD of -0.22 indicates Negative momentum. The RSI at 35.43 is Neutral, neither overbought nor oversold. The STOCH value of 30.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2575.
Xuanzhu Biopharmaceutical Co., Ltd. Class H Peers Comparison
Overall Rating
HK:369274.5Outperform
HK:998956Neutral
HK:255252Neutral
HK:618551Neutral
HK:001345Neutral- HK:257543Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:3692 | 75Outperform | HKD 196.24B | 24.91 | 18.26% | 1.50% | 24.97% | 43.23% |
| HK:9989 | 56Neutral | HKD 14.42B | 185.14 | 1.58% | 4.22% | 3.10% | -46.64% |
| HK:2552 | 52Neutral | HKD 2.11B | -18.06 | -10.61% | ― | 83.49% | -110.21% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:6185 | 51Neutral | HKD 13.23B | 632.61 | 0.60% | ― | 36.09% | ― |
| HK:0013 | 45Neutral | HKD 18.13B | 143.19 | 1.43% | ― | -8.55% | -96.20% |
| HK:2575 | 43Neutral | HKD 4.45B | -18.04 | -15.68% | ― | 237.19% | 61.28% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:2575 | Xuanzhu Biopharmaceutical Co., Ltd. Class H | 7.73 | -57.52 | -88.15% | |
| HK:0013 | HUTCHMED (China) Limited | 20.72 | -3.58 | -14.73% | |
| HK:2552 | Hua Medicine | 2.17 | -1.18 | -35.22% | |
| HK:9989 | Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H | 3.99 | -1.26 | -24.07% | |
| HK:3692 | Hansoh Pharmaceutical Group Company Limited | 31.98 | -3.19 | -9.07% | |
| HK:6185 | CanSino Biologics, Inc. Class H | 25.70 | -19.72 | -43.42% |
Xuanzhu Biopharmaceutical Co., Ltd. Class H Corporate Events
Xuanzhu’s Anaprazole Shows Strong Phase III Data in Reflux Esophagitis at UEG Week
Xuanzhu Biopharmaceutical Co., Ltd. announced that Phase III clinical data for its innovative proton pump inhibitor Anaprazole Sodium Enteric-coated Tablets in reflux esophagitis were presented as a Late-Breaking oral abstract at UEG Week 2026 in Bar...
Xuanzhu Biopharmaceutical Flags Share Price Surge Amid Early-Stage Acquisition Talks
Xuanzhu Biopharmaceutical Co., Ltd. reported unusual price movements in its Hong Kong-listed H shares, noting a sharp increase in the stock on the day of the announcement. The board stated that, after reasonable inquiries, it was not aware of any und...
Xuanzhu Biopharma INEDs Report No Conflicts With Controlling Shareholders in 2025 Review
Xuanzhu Biopharmaceutical Co., Ltd., a Hong Kong-listed Chinese biopharma group, has established governance measures to manage potential conflicts of interest with its controlling shareholders, relying on independent non-executive directors to review...
Xuanzhu Biopharma Strikes Thailand Commercial Deal for Breast Cancer Drug Bireociclib
Xuanzhu Biopharmaceutical has signed a tri-party commercial agreement with Thailand’s Innobic (Asia) and Hong Kong-based ZaoAn International, granting them exclusive rights to commercialise its breast cancer drug Bireociclib in Thailand through...
Xuanzhu Biopharmaceutical Narrows Interim Loss as Revenue Surges on New Products
Xuanzhu Biopharmaceutical reported interim revenue of RMB69.4 million for the six months ended June 30, 2026, a 288.1% jump from a year earlier as sales volumes rose on the back of new product launches and broader reimbursement coverage. Operating ex...
Xuanzhu Biopharmaceutical Sets Board Meeting to Approve 2026 Interim Results
Xuanzhu Biopharmaceutical has scheduled a board meeting for August 26, 2026 to review and approve its interim results for the six months ended June 30, 2026, and to authorize their publication. The board will also consider whether to recommend the pa...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 30, 2026